Coronavirus: Chinese regulator says vaccines must have 50 per cent efficacy, give 6 months’ immunity

Covid-19 vaccines must have an efficacy rate of 50 per cent and provide at least six months’ immunity if they are to be approved for use in China, the country’s drug regulator has announced.

Get the latest insights and analysis from our Global Impact newsletter on the big stories originating in China. China’s requirement for a minimum 50 per cent efficacy – which means the vaccine would protect half of those injected with it – is in line with the benchmarks set by the World Health Organisation and US Food and Drug Administration .

As phase three clinical trials can take up to a year to complete, the CCDE said it would consider allowing the use of vaccine candidates that had produced satisfactory efficacy data before the formal testing was complete. The FDA earlier made a similar statement. The CCDE said its standards were drafted after receiving feedback from more than 50 experts and 37 teams of scientists, and that their requirements took into consideration those of the WHO.

Singapore Latest News, Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Indonesia reports 2,354 new coronavirus cases, 50 more deathsJAKARTA: Indonesia on Saturday (Aug 15) reported 2,345 new coronavirus cases, taking the total number of infections to 137,468, according to data ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Kiss92 FM and One FM 91.3 programme director Jamie Meldrum dies at 50Former DJ and senior programme director at Kiss92 FM and One FM 91.3 Jamie Meldrum has died at the age of 50.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »

Explainer: How do vaccines and immune systems work, and why could a coronavirus vaccine fail?
Source: TODAYonline - 🏆 1. / 99 Read more »

Mexico needs 200 million COVID-19 vaccine doses; shots could start in AprilMexico will need up to 200 million coronavirus vaccine doses, according to a senior government official, and inoculation of its 120 million ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

China Sinopharm's potential COVID-19 vaccine triggers antibodies in clinical trialsBEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Coronavirus vaccine developer CureVac raises US$213 million in IPO: sourceCureVac BV raised US$213 million in its initial public offering on Thursday, a person familiar with the matter said, setting the stage for the ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »